Crotonylfentanyl is an opioid pain reliever, structurally related to fentanyl, and a structural isomer of cyclopropylfentanyl. It has been available on the internet as a designer drug. In December 2019, the United Nations Office on Drugs and Crime (UNODC) introduced scheduling recommendations to classify crotonylfentanyl as a Schedule I substance.
Crotonylfentanyl is a synthetic opioid analgesic. It is structurally similar to fentanyl and shares a structural isomer, cyclopropyl fentanyl.
How has Crotonylfentanyl been used?
Crotonylfentanyl has been marketed and sold as a designer drug, often through online channels.
What is the significance of classifying Crotonylfentanyl as a Schedule I substance?
The classification of Crotonylfentanyl as a Schedule I substance, as recommended by the United Nations Office on Drugs and Crime (UNODC), indicates that it is considered a substance with a high potential for abuse, no currently accepted medical use, and poses severe safety concerns. This classification can lead to legal restrictions and penalties for its possession and distribution.
Are there health risks associated with Crotonylfentanyl use?
Yes, like other potent synthetic opioids, the use of Crotonylfentanyl is associated with significant health risks, including the potential for overdose, respiratory depression, and addiction. It can be life-threatening, and its use should be strongly discouraged.
Is Crotonylfentanyl legal anywhere?
The legal status of Crotonylfentanyl can vary by country and region. However, many countries have taken measures to control and restrict its availability due to its potential dangers.
Where can individuals seek help for opioid-related issues or addiction?
If you or someone you know is struggling with opioid-related issues or addiction, it is essential to seek professional help immediately. Addiction treatment centers, healthcare providers, and addiction helplines are valuable resources for guidance and support in overcoming opioid addiction.
References
Mallette, Jennifer R.; Casale, John F.; Hays, Patrick A. (January 2019): “Characterization and Differentiation of Cyclopropylfentanyl from E-crotonylfentanyl, Z-crotonylfentanyl, and 3-butenylfentanyl.” Published in Science & Justice. Volume 59, Issue 1, pages 67–74. doi: 10.1016/j.scijus.2018.07.005. ISSN: 1355-0306. PMID: 30654970. S2CID: 58646707.
Varshneya, Neil B.; Walentiny, D. Matthew; Moisa, Lea T.; Walker, Teneille D.; Akinfiresoye, Luli R.; Beardsley, Patrick M. (June 2019): “Opioid-like Antinociceptive and Locomotor Effects of Emerging Fentanyl-Related Substances.” Published in Neuropharmacology. Volume 151, pages 171–179. doi: 10.1016/j.neuropharm.2019.03.023. ISSN: 0028-3908. PMC: 8992608. PMID: 30904478. S2CID: 84182661.
Palaty J, Konforte D, Karakosta T, Wong E, Stefan C (March 2018): “Rapid Identification of Cyclopropyl Fentanyl/Crotonyl Fentanyl in Clinical Urine Specimens: A Case Study of Clinical Laboratory Collaboration in Canada.” Published in Clinical Biochemistry. Volume 53, pages 164–167. doi: 10.1016/j.clinbiochem.2018.01.013. PMID: 29395089.
“December 2019 – WHO: World Health Organization Recommends 12 NPS for Scheduling.”
